Islam et al. (2017) have identified HDAC10 inhibitors as potential therapeutic targets for ovarian cancer, enhancing the efficacy of platinum drugs in malignant ovarian tumors. In addition, studies have shown that silencing HDAC1 by siRNA targeting leads to the induction of xenograft tumors that are sensitive to cisplatin therapy and can reduce drug resistance, which may be an effective strategy to improve the efficacy of cisplatin therapy (Liu et al., 2018). Here, HDAC10 is linked to ovarian carcinoma.